PCI Biotech Holding ASA reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was NOK 10.7 million compared to NOK 21.42 million a year ago. Basic loss per share from continuing operations was NOK 0.29 compared to NOK 0.57 a year ago.
For the nine months, net loss was NOK 48.4 million compared to NOK 63.34 million a year ago. Basic loss per share from continuing operations was NOK 1.3.